Creatine, Guanidinoacetic Acid, and the Evidence Behind the Formula

Creatine Reserve™ brings six disclosed ingredients together in one scoop: creatine monohydrate, guanidinoacetic acid (GAA), taurine, calcium L-methylfolate, methylcobalamin, and pyridoxal-5′-phosphate (P5P). This page explains what is in the formula, why each ingredient belongs in the conversation, what the human literature does and does not show, and where a reader should resist a tidy marketing story.

The point is not to make a combination formula sound more proven than it is. The point is to make it easier to evaluate. Creatine has a large human literature. GAA is a direct biochemical precursor to creatine, but its human evidence base is far smaller. Taurine and the B vitamins have established physiological roles, yet that does not mean they have been shown to create a specific result when combined with GAA and creatine. Those distinctions matter.

At a glance: Creatine Reserve™ combines 5 g creatine monohydrate, 1 g GAA, 1.5 g taurine, calcium L-methylfolate, methylcobalamin, and P5P. Creatine monohydrate has the broadest human evidence base among these ingredients. GAA research in humans is early, and no clinical trial has tested this finished formula. The sections below distinguish established physiology from preliminary studies and product-specific unknowns.

No clinical trial has tested this finished six-ingredient formula for any outcome. The research discussed below concerns individual ingredients or combinations that differ from this product in dose, form, population, duration, or all of the above. That is a limitation of the evidence, not fine print.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

What Is in Creatine Reserve™

Each scoop contains the following six ingredients.

 

 

That table is the first reason to consider this formula: it tells you exactly what is present, in what form, and at what amount. It does not ask you to infer a clinical outcome from an ingredient list. It also makes comparison possible. A person can compare the formula against their current approach, the published studies, their clinician’s guidance, and other supplements they may already be using.

The creatine dose sits within a commonly used maintenance range. The International Society of Sports Nutrition position stand describes 3 to 5 g/day as a typical maintenance range after muscle stores are raised, while noting that requirements can vary by body size and training context (Kreider et al., 2017). The 1 g GAA amount is not presented as a clinically proven “sweet spot.” It matches the GAA amount used in one small, four-week human combination pilot, but that pilot paired 1 g GAA with 3 g creatine, not with the 5 g creatine in this formula (Semeredi et al., 2019).

The other ingredient amounts should be read just as carefully. The methyl-donor study often cited in GAA marketing used 2.4 g GAA with betaine hydrochloride, folic acid, vitamin B6, and vitamin B12 at doses and forms different from this product (Ostojic et al., 2013). The research does not test this exact six-ingredient arrangement. Transparent formulation means saying that plainly before discussing the pathway.

What Is the Short Version on This Formula?

Creatine Reserve™ is a multi-ingredient dietary supplement, not a clinically tested replacement for plain creatine monohydrate. It is designed around a real biochemical sequence: the body synthesizes creatine from GAA through a methylation step, and creatine participates in the phosphocreatine energy system. That sequence is well established physiology.

What is less established is whether adding GAA, taurine, and the listed B vitamins to 5 g of creatine monohydrate produces a meaningful advantage over creatine monohydrate alone. The available combination evidence is preliminary. A small crossover study of 14 healthy young men reported favorable point estimates for 1 g GAA plus 3 g creatine versus 4 g creatine, but its reported between-condition confidence intervals included zero and it did not test this formula (Semeredi et al., 2019).

That leaves a reasonable, but narrower, commercial proposition: one scoop provides the listed ingredients in the listed forms and amounts, accompanied by a candid explanation of the evidence. It does not establish a plateau remedy, a superior route to muscle creatine, a cognitive benefit, a cardiovascular benefit, a longevity benefit, or a way to control homocysteine in every user.

For some adults who choose to supplement with creatine, plain creatine monohydrate remains a well-studied option. For readers who want the listed combination rather than several separate ingredients, this formula makes the composition visible and the limits explicit.

What Does the Creatine Evidence Actually Show?

Creatine is the most extensively studied ingredient in this formula. The body obtains creatine from dietary sources and endogenous synthesis, and it stores most of its total creatine in muscle tissue. A classic physiology review describes more than 90% of total body creatine as being found in muscle tissue; in a 70 kg person with a total creatine pool of roughly 120 g, about 2 g per day is converted to creatinine and must be replaced through diet or synthesis (Wyss & Kaddurah-Daouk, 2000). These are population-level approximations, not a prescription for an individual.

Creatine monohydrate is also the form with the broadest exercise and sports-nutrition literature. That does not make every outcome relevant to every person, every training program, or every product containing creatine. It does mean that creatine monohydrate has been studied in more human contexts than GAA, taurine, or the finished combination presented here.

A 2024 systematic review and dose-response meta-analysis reported a weighted mean increase of 0.82 kg in fat-free mass across its pooled analysis of creatine protocols. The authors described the body-composition findings as more robust when creatine was combined with resistance training (Pashayee-Khamene et al., 2024). That is useful context for understanding the ingredient literature, but it is not a result from a trial of Creatine Reserve™.

“Fat-free mass” also deserves careful reading. It is not the same as a direct measure of contractile muscle tissue, and it can include water. Creatine changes cellular and total body water dynamics in some contexts, which is one reason a responsible discussion should not convert a fat-free-mass finding into a promise of a certain amount of new muscle for a particular person.

Creatine’s evidence is strongest where the study design, ingredient, population, dose, and endpoint line up with the question being asked. It becomes less direct when an outcome is moved from resistance-trained adults to an unrelated population, from creatine monohydrate to a combination formula, or from a measured variable to a broader promise. This page keeps those boundaries visible.

How Does Creatine Work in Cells?

At a basic level, creatine is part of the phosphagen energy system. In cells with high and fluctuating energy demand, the creatine kinase reaction interconverts creatine and phosphocreatine while shuttling phosphate groups in relation to ATP and ADP. Phosphocreatine can function as a rapidly available phosphate reserve during short periods of high energy demand (Wyss & Kaddurah-Daouk, 2000).

That mechanism explains why creatine has long been of interest in high-intensity exercise research. It is a mechanism, however, not a guarantee. The existence of the phosphocreatine system does not demonstrate that every person will notice the same effect, that every dosage protocol produces the same result, or that any formula containing creatine is clinically distinct.

The mechanism also helps explain why muscle creatine content is central to many supplementation studies. Supplementation can increase muscle creatine stores, but the response is influenced by baseline stores, diet, muscle fiber characteristics, body size, dose, and protocol. People do not begin from identical baselines, and they should not expect identical measured changes.

This is one reason the phrase “more is always better” does not belong in responsible creatine education. The goal of a standard loading or maintenance protocol is not to create an unlimited creatine pool. Muscle stores are finite. Supplementation protocols differ largely in how quickly they raise stores and how those stores are subsequently maintained.

How Do Creatine Loading and Maintenance Approaches Compare?

Two evidence-based ways of using creatine are often discussed in research: a loading approach and a lower, steady daily approach. A loading protocol is commonly described as approximately 0.3 g/kg/day of creatine monohydrate for 5 to 7 days, followed by 3 to 5 g/day to maintain elevated stores. A lower daily intake of 3 to 5 g/day can also raise muscle creatine over approximately 3 to 4 weeks (Kreider et al., 2017).

The classic Hultman study illustrates the difference in pace. In healthy men, 20 g/day for six days rapidly increased muscle creatine, while 3 g/day for 28 days produced a similar but more gradual increase. After loading, 2 g/day maintained the increase during the study period (Hultman et al., 1996). This is useful context for timing expectations, not evidence that a particular protocol is necessary for everyone.

Another study compared post-loading maintenance doses of 2 g/day and 5 g/day over six weeks and found that both maintained elevated muscle total creatine concentrations after a five-day loading phase (Preen et al., 2003). That is one reason a 5 g dose can be described as a studied maintenance amount. It is still important not to treat a maintenance dose as a claim that a finished multi-ingredient formula has been tested or shown superior.

The practical distinction is simple. Loading is a faster route to elevated muscle stores. Lower daily dosing is a slower route. Neither approach supports the claim that supplementation “restarts” a malfunctioning system, prevents a training plateau, or makes another ingredient necessary.

What Is the AGAT/GAMT Pathway and Where Does GAA Fit?

The body synthesizes creatine in a two-step pathway. First, arginine:glycine amidinotransferase, commonly called AGAT, combines arginine and glycine to form guanidinoacetate, also called guanidinoacetic acid or GAA. Second, guanidinoacetate methyltransferase, commonly called GAMT, transfers a methyl group to GAA to form creatine. The formation of GAA through AGAT is generally described as the rate-limiting or major control step in creatine biosynthesis (Wyss & Kaddurah-Daouk, 2000).

The anatomy is often summarized as “kidney to liver,” because AGAT activity is prominent in the kidney and GAMT activity is prominent in the liver. In reality, the pathway is distributed across tissues, and physiology rarely follows a marketing diagram perfectly. What matters for this page is the basic sequence: GAA is the direct substrate GAMT converts into creatine.

That is a factual reason to discuss GAA alongside creatine. It is not proof that ingesting GAA with creatine creates a second, superior human delivery route. Transport and tissue-conversion research is more complex than that framing suggests, and much of it comes from animal or in-vitro work. A biochemical relationship is not the same as a demonstrated product advantage.

The pathway also provides context for why methyl-group metabolism appears in a GAA discussion. GAMT uses S-adenosylmethionine, or SAM, as a methyl donor when it converts GAA to creatine. The downstream handling of homocysteine involves folate, vitamin B12, and vitamin B6. That is physiology. It does not establish that including those vitamins in a specific formula has been shown to produce a specific homocysteine outcome.

Does Creatine “Shut Down” Your AGAT Enzyme?

You may have encountered a claim that long-term creatine use shuts down AGAT, stops the body from making creatine, causes a plateau, and therefore makes GAA necessary to “restart” a second engine. It is an appealing story because it combines a real feedback mechanism with a familiar training frustration. It goes further than the evidence.

Rodent research does show feedback effects. In rat kidney, dietary creatine repressed AGAT synthesis at a pretranslational level (McGuire et al., 1984). In a rat-pancreas study, creatine supplementation reduced AGAT activity, but AGAT mRNA and protein levels did not fall. The authors therefore observed a different regulatory pattern from the kidney finding (da Silva et al., 2014).

Those studies are important because they show that creatine biosynthesis is regulated. They are not evidence that a person using creatine monohydrate reaches a felt “plateau” because endogenous synthesis has shut down. They also do not show that adding GAA reverses a human training plateau or restores a clinically meaningful outcome.

Supplemental creatine directly contributes to the creatine pool being studied in muscle. When someone takes creatine, the immediate question is not whether endogenous synthesis is the only thing filling muscle stores; supplementation itself changes the input. That is why the familiar loading-versus-steady-dose studies are more useful to an evidence-based discussion than an unsupported “dead engine” narrative.

The useful takeaway is modest: creatine synthesis is feedback-regulated, GAA is a direct precursor in that pathway, and human formula-level advantages remain unproven. A more dramatic takeaway would not be better science.

What Does Human GAA Research Show?

GAA is a legitimate research topic, but it is not supported by the breadth of human evidence available for creatine monohydrate. Much of the GAA literature comes from animal nutrition, mechanistic work, or small human studies. That does not make GAA irrelevant. It does mean the language used around it should match the evidence base.

The most directly relevant human study for a creatine-plus-GAA discussion was a randomized, double-blind crossover trial in 14 healthy young men. Participants took either 1 g GAA plus 3 g creatine or 4 g creatine for four weeks, separated by a 28-day washout. Investigators used proton magnetic resonance spectroscopy to assess tissue creatine and also evaluated exercise outcomes (Semeredi et al., 2019).

The study’s reported within-arm changes and point estimates favored the GAA-plus-creatine condition for several measurements. But the reported between-condition confidence intervals included zero. For example, the estimated difference in muscle creatine had a 95% confidence interval of −6.8% to 36.6%, which includes no difference. The study was small, short, and did not compare equal amounts of creatine across the two conditions. It is best read as hypothesis-generating rather than as confirmation that adding GAA creates a superior result.

It also did not test this formula. The trial used 1 g GAA plus 3 g creatine; Creatine Reserve™ lists 1 g GAA plus 5 g creatine, as well as taurine and three B vitamins. A small trial of a different two-ingredient regimen cannot substantiate efficacy claims for a six-ingredient formula.

The trial itself reported Serbian institutional funding and no conflicts of interest. In a separate 2023 publication, the senior investigator, S. M. Ostojic, disclosed Scientific Advisory Board membership at AlzChem LLC and recent research support from AlzChem GmbH, among other entities (Ostojic et al., 2023). Those are distinct disclosures. Transparency means neither erasing the 2019 paper’s stated disclosure nor treating the later disclosure as proof that the 2019 trial itself was industry funded.

Why Are GAA, Methylation, Homocysteine, and B Vitamins Discussed Together?

GAA deserves a second careful conversation because GAMT uses a methyl group to convert it into creatine. SAM is a major methyl donor in metabolism. After SAM donates a methyl group, it becomes S-adenosylhomocysteine, which can be broken down to homocysteine.

Homocysteine then sits at a metabolic intersection. Through remethylation, it can be recycled toward methionine in pathways that use folate and vitamin B12. Through transsulfuration, it can be directed toward cysteine-related metabolism in a pathway requiring vitamin B6. This is why folate, B12, B6, GAA, creatine synthesis, and homocysteine are frequently discussed in the same technical conversation.

The methyl-demand literature needs qualification. A 2001 rat study described GAA methylation as consuming a large share of labile methyl groups, while a later review estimated creatine synthesis at approximately 40% of SAM-derived labile methyl groups under the conditions discussed (Stead et al., 2001; Brosnan et al., 2011). The magnitude is not a fixed human percentage. It varies with diet, physiology, and experimental context, and the earlier, larger estimate was later reconsidered by the same research group (Stead et al., 2006).

GAA and homocysteine have been tested in small human studies. In one randomized, placebo-controlled, double-blind six-week study, 48 healthy volunteers received 1.2 g, 2.4 g, or 4.8 g GAA per day. Average fasting plasma total homocysteine increased by 3.5 µmol/L in the GAA groups, but the paper reported no dose-response differences for homocysteine across those GAA trials (Ostojic et al., 2014). That is an important detail: the study does not support a simple claim that higher GAA dose produced a neatly proportional homocysteine response.

Another small study evaluated 2.4 g/day GAA alone versus 2.4 g/day GAA with 1.6 g betaine hydrochloride, 600 mcg folic acid, 10 mg vitamin B6, and 5 mcg vitamin B12. The reported incidence of hyperhomocysteinemia was lower in the combined methyl-donor condition than in the GAA-alone condition (Ostojic et al., 2013). But the trial did not use calcium L-methylfolate, methylcobalamin, or P5P, and it did not test 1 g GAA with 5 g creatine plus taurine.

That difference is not technical trivia. It determines what can responsibly be claimed. The biochemistry explains why B vitamins appear in this formula. It does not establish that the formula prevents, offsets, normalizes, or controls a GAA-related homocysteine change in users. No clinical trial has tested that question for this finished formula.

Why Does the Formula Disclose These Ingredient Forms?

The formula identifies chemical forms instead of using only broad nutrient names. That is useful because the form is part of the product specification and part of how a reader compares one formula with another. It is not, by itself, a claim that one form is clinically superior for every person or every outcome.

 

 

Creatine monohydrate is a straightforward example of why naming forms can be informative. It is the form used in the established loading and maintenance literature discussed above. Naming it gives a reader enough information to compare the product against that research. It does not mean the product as a whole has been tested in the same way as creatine monohydrate alone.

For folate, calcium L-methylfolate identifies the methylated form used in the formula. For vitamin B12, methylcobalamin identifies the B12 form. For vitamin B6, P5P identifies a phosphate form of the vitamin. These are facts about composition. They should not be inflated into “best form,” “most bioavailable,” or “works regardless of MTHFR genotype” claims without product- and outcome-relevant substantiation.

The two commonly discussed folate trials do not justify a genotype claim for this formula. Venn and colleagues did not genotype participants; their study compared low-dose folic acid, L-5-methyltetrahydrofolate, and placebo in healthy volunteers and found a greater homocysteine-lowering effect with L-5-methyltetrahydrofolate at the study dose (Venn et al., 2003). Zappacosta and colleagues studied individuals with moderate hyperhomocysteinemia and compared a folate-rich diet, 5-methyltetrahydrofolate, and folic acid at a different dose from this formula (Zappacosta et al., 2013). Neither study establishes a genotype-independent, finished-product advantage at the dose listed here.

The commercial value of named forms is transparency. It gives a buyer a complete formulation record. It does not give a brand permission to imply personalized genetic superiority.

What Does Taurine Research Show in This Context?

Taurine is a sulfur-containing amino acid. It is involved in bile-acid conjugation, cellular osmoregulation, calcium handling, and aspects of mitochondrial biology (Schaffer & Kim, 2018). Those are established physiological roles, and they explain why taurine appears frequently in nutrition discussions that focus on high-demand tissues and cellular homeostasis.

Creatine Reserve™ provides 1,500 mg taurine per scoop. No clinical trial has tested taurine’s contribution within this finished combination. That is the relevant limitation for this product page.

Human taurine research includes systematic reviews and meta-analyses of cardiovascular and metabolic-syndrome-related outcomes. The included evidence in those reviews comes largely from clinical or disease-adjacent populations and should not be repurposed into broad benefit claims for a general adult supplement formula (Tzang et al., 2024a; Tzang et al., 2024b).

The longevity discussion needs the same restraint. A 2023 Science paper reported that taurine supplementation extended median lifespan in middle-aged mice. The human part of the paper included observational analyses and acute exercise metabolite observations, not a human taurine-supplementation lifespan trial. The authors themselves called for human clinical trials (Singh et al., 2023). Mouse lifespan findings are a reason for scientific interest, not evidence that this formula extends human lifespan.

Taurine belongs on this page because it is in the formula and because its physiology can be explained accurately. The responsible commercial approach is not to borrow outcomes from clinical populations or mice and imply that they occur with a 1,500 mg taurine dose inside an untested combination.

What Has This Formula Not Been Shown to Do?

The strength of a transparent page is that it makes the non-claims easy to find. This formula has not been shown in a clinical trial to:

·       Build more muscle creatine than creatine monohydrate alone.

·       Break a training or supplementation plateau.

·       Reverse suppression of endogenous creatine synthesis.

·       Improve cognitive performance.

·       Improve cardiovascular or metabolic outcomes.

·       Produce a human longevity outcome.

·       Offset, prevent, normalize, or control a GAA-related change in homocysteine.

·       Deliver a distinct result because of its B-vitamin forms.

·       Produce a specific result when used with other dietary supplements or prescription medicines.

These are not rhetorical disclaimers. They are the exact boundaries created by the available evidence. The difference between educational content and overclaiming is often the willingness to say where the study ends.

The formula can still be marketed truthfully. It provides one scoop with 5 g creatine monohydrate, 1 g GAA, 1.5 g taurine, and the listed B-vitamin forms and amounts. It makes those decisions visible. It gives readers the direct study context rather than asking them to accept a mechanism story without limits.

For a reader considering the formula, the practical question is not “Has every mechanism been proven to create a unique outcome?” The evidence says no. The practical question is whether the disclosed ingredients and amounts match the approach the reader wants to take, after considering their health status, total supplement intake, and clinician guidance where appropriate.

What Safety and Use Context Should You Consider?

 

This finished formula has not been evaluated in a long-term clinical safety study. The information below is general education and does not replace individual medical advice. A qualified healthcare professional can help assess whether a supplement fits a person’s health history, medications, laboratory results, and total nutrient intake.

Vitamin B6

The formula lists 20 mg of vitamin B6 as P5P. In 2023, the European Food Safety Authority set a tolerable upper intake level of 12 mg/day for adults, covering dietary and supplemental intake from all vitamin B6 vitamers, including pyridoxal 5′-phosphate (P5P/PLP) (EFSA NDA Panel, 2023). The 20 mg in this formula exceeds that European reference value.

This is not a U.S. upper limit. It is an EFSA value for the general European population, and it should be described that way. EFSA based the upper level on evidence linking excess vitamin B6 intake with peripheral neuropathy. The fact that P5P is the listed B6 form does not exempt it from the EFSA all-vitamer framework.

If you use other B6-containing products, account for total intake across your regimen. If you notice tingling, numbness, or other possible nerve-related symptoms, stop using the product and consult a qualified healthcare professional. This is a material safety point, not a marketing footnote.

Kidney function and creatinine

Creatinine is a breakdown product related to creatine metabolism, so creatine supplementation can complicate interpretation of serum creatinine values. A 2025 systematic review and meta-analysis found a modest increase in serum creatinine while finding no statistically significant difference in pooled glomerular filtration rate from five studies. The authors also noted that long-term safety data beyond one year were sparse (Kabiri Naeini et al., 2025).

That finding should not be converted into a blanket medical assurance. If you have kidney disease, reduced kidney function, or are being monitored for kidney-related concerns, discuss creatine-containing supplements with a qualified healthcare professional before use. Bring the complete product label and your current supplement list to that conversation.

GAA and homocysteine

Small human GAA studies have reported homocysteine changes under some study conditions. The six-week, 48-participant study described earlier found an average increase in fasting total homocysteine across the GAA groups, without a reported dose-response difference for homocysteine (Ostojic et al., 2014). The finished formula has no long-term clinical safety study and no product-specific homocysteine data.

The formula’s folate, B12, and B6 content should not be treated as evidence that it changes that outcome. People with individual questions about homocysteine testing or methylation-related concerns should discuss them with a qualified healthcare professional rather than use self-directed testing as a substitute for care.

Taurine dose context

An observed safe level of 6 g/day of taurine for up to one year has been cited in regulatory discussions. It is an observed safe level, not a formal tolerable upper intake level. The underlying safety discussion also distinguishes people with normal kidney function from a small hemodialysis study, in which high doses were associated with adverse symptoms (U.S. Food and Drug Administration, 2015). The 1,500 mg taurine in this formula is below that figure, but a comparison to an observed safe level does not establish the safety of the finished formula or of long-term use.

Pregnancy, breastfeeding, age, medications, and total intake

Do not use this product during pregnancy or breastfeeding. It is not for individuals under 18. These restrictions should match the final approved product label and internal regulatory guidance.

This formula has not been studied alongside other dietary supplements or prescription medicines. Consult a qualified healthcare professional about your complete regimen, particularly if you take medicines or manage conditions that affect kidney function, nutrient status, or laboratory monitoring.

What Does the WADA List Mean for This Formula?

 

None of the six listed ingredients appears by name on the 2026 World Anti-Doping Agency Prohibited List (World Anti-Doping Agency, 2026). That is a narrow statement about the list. It is not a product certification, a batch-contamination guarantee, or an assurance that a particular sporting organization will treat a product in a specific way.

WADA does not certify dietary-supplement products or batches. For tested athletes, the relevant question is whether a specific product and, where applicable, a specific batch has been certified through an independent sport-testing program. This page does not represent Creatine Reserve™ as certified by a sport-testing program. Tested athletes should check the product’s current certification status and their sport organization’s requirements before relying on a supplement.

Frequently Asked Questions About Creatine and GAA

Has the finished formula been tested in a clinical trial?

No. The research discussed here concerns individual ingredients or different combinations. No clinical trial has tested the finished six-ingredient Creatine Reserve™ formula for an outcome.

Why include GAA with creatine?

GAA is the direct substrate GAMT converts to creatine in endogenous creatine synthesis. One small human pilot studied 1 g GAA plus 3 g creatine against 4 g creatine, but it did not test this formula and did not establish a definitive advantage for the combination. GAA is less extensively studied in humans than creatine.

Does the formula use a clinically proven GAA-plus-creatine dose?

No. The formula lists 1 g GAA plus 5 g creatine. The small pilot used 1 g GAA plus 3 g creatine, and it was not a study of the finished formula. “Clinically proven” would not be an accurate description.

Does the formula’s B-vitamin blend control homocysteine?

That has not been shown. The biochemical pathways are connected, and a separate small study tested a different GAA-plus-methyl-donor combination, but no clinical trial has tested whether the forms and amounts in this finished formula change a GAA-related homocysteine response.

Why list the forms of folate, B12, and B6?

The form is part of the formulation. Calcium L-methylfolate, methylcobalamin, and P5P are the specific forms listed in the formula. Naming forms helps a reader evaluate the Supplement Facts panel. It is not a claim that these forms have been shown to be superior for a particular outcome in this product.

Will it build more muscle creatine than plain creatine?

That has not been shown for this formula. The only directly relevant combination evidence is one small, short study with a different creatine amount, and its reported between-condition confidence intervals included zero.

Is plain creatine monohydrate still a reasonable option?

Yes. Creatine monohydrate remains the ingredient in this category with the larger human literature. A combination formula is not automatically a better choice than plain creatine. The choice depends on the ingredients a person wishes to use, their total regimen, and appropriate professional guidance.

Is this “WADA compliant”?

That phrase is too broad. The listed ingredients do not appear on the 2026 WADA Prohibited List, but WADA does not certify products or batches. This page does not represent the product as certified by a sport-testing program. Tested athletes should use the sport-certification standard required by their organization.

Can I take it with other supplements or medications?

This formula has not been studied in combination with other dietary supplements or prescription medicines. Discuss your full regimen with a qualified healthcare professional, particularly if you have a medical condition, take prescription medicines, or are monitoring kidney-related laboratory values.

How Should You Evaluate a Combination Formula?

Supplement marketing often asks a reader to accept an outcome first and inspect the evidence later. A better order is the reverse.

Start with the product facts. Creatine Reserve™ lists 5 g creatine monohydrate, 1 g GAA, 1.5 g taurine, and the stated folate, B12, and B6 forms and amounts per scoop. Then look at the human evidence. Creatine monohydrate has a large literature. GAA is a direct precursor with early, limited human combination data. The B-vitamin and homocysteine connection is real biochemistry, but a finished-formula outcome has not been tested. Taurine has established physiological roles and a diverse research literature, but no trial has established its contribution to this formula.

Then look at what is missing. There is no finished-formula clinical trial. There is no evidence that the formula breaks a plateau, creates a human longevity result, or outperforms plain creatine. There is no product-specific trial showing that its B-vitamin forms manage GAA-related homocysteine changes.

That is not a reason to hide the formula. It is a reason to describe it accurately. The formula offers disclosed ingredients in one scoop, with a full account of what the cited studies actually tested. For readers who value formulation transparency and want to make an informed choice, that is the product information that should come first.

Continue your research: Creatine and Guanidinoacetic Acid: A Research-Grounded Guide.

For the current Supplement Facts panel, directions, and product-use information, visit: Product Details and Full Ingredient Panel.

See the current product page for pricing, availability, and return-policy terms.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Scientific References & Citations

Brosnan, J. T., da Silva, R. P., & Brosnan, M. E. (2011). The metabolic burden of creatine synthesis. Amino Acids, 40(5), 1325–1331. https://doi.org/10.1007/s00726-011-0853-y

da Silva, R. P., Clow, K., Brosnan, J. T., & Brosnan, M. E. (2014). Synthesis of guanidinoacetate and creatine from amino acids by rat pancreas. British Journal of Nutrition, 111(4), 571–577. https://doi.org/10.1017/S0007114513003012

EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA). (2023). Scientific opinion on the tolerable upper intake level for vitamin B6. EFSA Journal, 21(5), e08006. https://doi.org/10.2903/j.efsa.2023.8006

Hultman, E., Söderlund, K., Timmons, J. A., Cederblad, G., & Greenhaff, P. L. (1996). Muscle creatine loading in men. Journal of Applied Physiology, 81(1), 232–237. https://doi.org/10.1152/jappl.1996.81.1.232

Kabiri Naeini, E., Eskandari, M., Mortazavi, M., Gholaminejad, A., & Karevan, N. (2025). Effect of creatine supplementation on kidney function: A systematic review and meta-analysis. BMC Nephrology, 26, 622. https://doi.org/10.1186/s12882-025-04558-6

Kreider, R. B., Kalman, D. S., Antonio, J., Ziegenfuss, T. N., Wildman, R., Collins, R., Candow, D. G., Kleiner, S. M., Almada, A. L., & Lopez, H. L. (2017). International Society of Sports Nutrition position stand: Safety and efficacy of creatine supplementation in exercise, sport, and medicine. Journal of the International Society of Sports Nutrition, 14, Article 18. https://doi.org/10.1186/s12970-017-0173-z

McGuire, D. M., Gross, M. D., Van Pilsum, J. F., & Towle, H. C. (1984). Repression of rat kidney L-arginine:glycine amidinotransferase synthesis by creatine at a pretranslational level. Journal of Biological Chemistry, 259(19), 12034–12038. https://pubmed.ncbi.nlm.nih.gov/6384218/

Ostojic, S. M., Niess, B., Stojanovic, M., & Obrenovic, M. (2013). Co-administration of methyl donors along with guanidinoacetic acid reduces the incidence of hyperhomocysteinaemia compared with guanidinoacetic acid administration alone. British Journal of Nutrition, 110(5), 865–870. https://doi.org/10.1017/S0007114512005879

Ostojic, S. M., Ratgeber, L., Trunic, N., & Rajkovic, S. (2023). Cataloguing guanidinoacetic acid content in nutritional supplements. Food Science & Nutrition, 11, 1603–1605. https://doi.org/10.1002/fsn3.3206

Ostojic, S. M., Stojanovic, M., Drid, P., & Hoffman, J. R. (2014). Dose-response effects of oral guanidinoacetic acid on serum creatine, homocysteine and B vitamins levels. European Journal of Nutrition, 53(8), 1637–1643. https://doi.org/10.1007/s00394-014-0669-0

Pashayee-Khamene, F., Heidari, Z., Asbaghi, O., Ashtary-Larky, D., Goudarzi, K., Forbes, S. C., Candow, D. G., Bagheri, R., Ghanavati, M., & Dutheil, F. (2024). Creatine supplementation protocols with or without training interventions on body composition: A GRADE-assessed systematic review and dose-response meta-analysis. Journal of the International Society of Sports Nutrition, 21(1), 2380058. https://doi.org/10.1080/15502783.2024.2380058

Preen, D., Dawson, B., Goodman, C., Beilby, J., & Ching, S. (2003). Creatine supplementation: A comparison of loading and maintenance protocols on creatine uptake by human skeletal muscle. International Journal of Sport Nutrition and Exercise Metabolism, 13(1), 97–111. https://doi.org/10.1123/ijsnem.13.1.97

Schaffer, S. W., & Kim, H. W. (2018). Effects and mechanisms of taurine as a therapeutic agent. Biomolecules & Therapeutics, 26(3), 225–241. https://doi.org/10.4062/biomolther.2017.251

Semeredi, S., Stajer, V., Ostojic, J., Vranes, M., & Ostojic, S. M. (2019). Guanidinoacetic acid with creatine compared with creatine alone for tissue creatine content, hyperhomocysteinemia, and exercise performance: A randomized, double-blind superiority trial. Nutrition, 57, 162–166. https://doi.org/10.1016/j.nut.2018.04.009

Singh, P., Gollapalli, K., Mangiola, S., Schranner, D., Yusuf, M. A., Chamoli, M., Shi, S. L., Lopes Bastos, B., Nair, T., Riermeier, A., Vayndorf, E. M., Wu, J. Z., Nilakhe, A., Nguyen, C. Q., Muir, M., Kiflezghi, M. G., Foulger, A., Junker, A., Devine, J., … Yadav, V. K. (2023). Taurine deficiency as a driver of aging. Science, 380(6649), eabn9257. https://doi.org/10.1126/science.abn9257

Stead, L. M., Au, K. P., Jacobs, R. L., Brosnan, M. E., & Brosnan, J. T. (2001). Methylation demand and homocysteine metabolism: Effects of dietary provision of creatine and guanidinoacetate. American Journal of Physiology-Endocrinology and Metabolism, 281(5), E1095–E1100. https://doi.org/10.1152/ajpendo.2001.281.5.E1095

Stead, L. M., Brosnan, J. T., Brosnan, M. E., Vance, D. E., & Jacobs, R. L. (2006). Is it time to reevaluate methyl balance in humans? The American Journal of Clinical Nutrition, 83(1), 5–10. https://doi.org/10.1093/ajcn/83.1.5

Tzang, C.-C., Lin, W.-C., Lin, L.-H., Lin, T.-Y., Chang, K.-V., Wu, W.-T., & Özçakar, L. (2024a). Insights into the cardiovascular benefits of taurine: A systematic review and meta-analysis. Nutrition Journal, 23, 93. https://doi.org/10.1186/s12937-024-00995-5

Tzang, C.-C., Chi, L.-Y., Lin, L.-H., Lin, T.-Y., Chang, K.-V., Wu, W.-T., & Özçakar, L. (2024b). Taurine reduces the risk for metabolic syndrome: A systematic review and meta-analysis of randomized controlled trials. Nutrition & Diabetes, 14, 29. https://doi.org/10.1038/s41387-024-00289-z

U.S. Food and Drug Administration. (2015, May 13). GRAS exemption claim for taurine for use in enhanced water beverages: GRAS notice 586. https://www.fda.gov/files/food/published/GRAS-Notice-000586---Taurine.pdf

Venn, B. J., Green, T. J., Moser, R., & Mann, J. I. (2003). Comparison of the effect of low-dose supplementation with L-5-methyltetrahydrofolate or folic acid on plasma homocysteine: A randomized placebo-controlled study. The American Journal of Clinical Nutrition, 77(3), 658–662. https://doi.org/10.1093/ajcn/77.3.658

World Anti-Doping Agency. (2026). The 2026 prohibited list. https://www.wada-ama.org/en/resources/world-anti-doping-code-and-international-standards/prohibited-list

Wyss, M., & Kaddurah-Daouk, R. (2000). Creatine and creatinine metabolism. Physiological Reviews, 80(3), 1107–1213. https://doi.org/10.1152/physrev.2000.80.3.1107

Zappacosta, B., Mastroiacovo, P., Persichilli, S., Pounis, G., Ruggeri, S., Minucci, A., Carnovale, E., Andria, G., Ricci, R., Scala, I., Genovese, O., Turrini, A., Mistura, L., Giardina, B., & Iacoviello, L. (2013). Homocysteine lowering by folate-rich diet or pharmacological supplementations in subjects with moderate hyperhomocysteinemia. Nutrients, 5(5), 1531–1543. https://doi.org/10.3390/nu5051531